Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Addeira Pharmaceuticals, also known as Addeira, is a prominent player in the pharmaceutical preparation manufacturing industry, headquartered in the SE region. Since its founding in [year], the company has established a strong presence across major markets, delivering high-quality pharmaceutical products and services.
Specialising in the development and production of innovative medicinal formulations, Addeira is recognised for its commitment to quality and regulatory compliance. Its core offerings include customised drug preparations and sterile products, which set it apart through advanced manufacturing techniques and rigorous quality standards.
With a reputation for reliability and excellence, Addeira Pharmaceuticals continues to grow its market share and contribute to healthcare advancements, making it a notable leader within the pharmaceutical manufacturing sector.
-13 vs industry average
Addeira Pharmaceuticals’s score of 29 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Addeira Pharmaceuticals yet.
As Addeira Pharmaceuticals, headquartered in SE, operates within the Pharmaceutical Preparation Manufacturing industry, their climate commitments focus on reducing greenhouse gas emissions.
Addeira Pharmaceuticals has committed to a Science Based Target (SBTi) to reduce their absolute Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2022 as a baseline year. This target is consistent with limiting global warming to 1.5°C. Additionally, the company pledges to measure and subsequently reduce its Scope 3 emissions.
Currently, no absolute emissions data for Addeira Pharmaceuticals is available for reporting. However, their commitment to SBTi signifies a proactive approach to climate action within their sector.
2030
42% reduction in Scope 1
Addeira Pharmaceuticals AB commits to reduce scope 1 GHG emissions 42% by 2030 from a 2022 base year.
2030
42% reduction in Scope 2
Addeira Pharmaceuticals AB commits to reduce scope 2 GHG emissions 42% by 2030 from a 2022 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more